- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 12, Issue 6, 2006
Current Pharmaceutical Design - Volume 12, Issue 6, 2006
Volume 12, Issue 6, 2006
-
-
Editorial [Hot Topic: Drug Targets in Alzheimer's Disease (Executive Editors: G. Munch and G. Stuchbury)]
Authors: Gerald Munch and Grant StuchburyAlzheimer's disease (AD) is the most common cause of dementia, affecting more than 30% of the population over 85 years of age. In 2002, the estimated cost of dementia in Western countries was about 1% of GDP, by 2050, this is expected to increase to about 3%. The development of neuroprotective pharmacological strategies is an important task for the research community. AD is characterized by two characteristic l Read More
-
-
-
γ-Secretase as a Therapeutic Target for Treatment of Alzheimer's Disease
Authors: Taisuke Tomita and Takeshi IwatsuboAlzheimer's disease (AD) is the most common cause of dementia with aging, that is pathologically characterized by senile plaques that contain amyloid-b peptides (Aβ) and neurofibrillary tangles comprised of phosphorylated tau. Genetic and biological studies provide evidence that the production and deposition of Aβ contribute to the etiology of AD. g-Secretase is the pivotal enzyme in generating the C terminus of Aβ, t Read More
-
-
-
Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Authors: Mohammed E. Mouedden, Marc Vandermeeren, Theo Meert and Marc MerckenConsiderable effort has been made to develop drugs that delay or prevent neurodegeneration. These include inhibitors of Aβ-generating proteases for the treatment of Alzheimer's disease. Testing the amyloid hypothesis in vivo requires molecules that are capable of entering the CNS and that produce a substantial reduction in brain Aβ levels. Plaque-developing APP transgenic mice are currently widely used as an in vivo model Read More
-
-
-
Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimer's Disease Pyramidal Neurons
Authors: Michael R. D'Andrea and Robert G. NageleAlthough there is still no known effective preventative treatment or cure for Alzheimer's disease (AD), the development of new drugs that target pathological features that appear early in the course of this disease and alleviate some of the early cognitive and memory symptoms is a laudable goal that may be one step closer. To date, the acetylcholinesterase inhibitors have been the most widely used AD drugs and have been s Read More
-
-
-
Antigonadotropins: A Novel Strategy to Halt Alzheimer's Disease Progression
Authors: Christopher W. Gregory, Craig S. Atwood, Mark A. Smith and Richard L. BowenA significant amount of research has been focused on the relationship between hormones and Alzheimer's disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimer's disease. The age-related Read More
-
-
-
The Cell Cycle and Hormonal Fluxes in Alzheimer Disease: A Novel Therapeutic Target
Several hypotheses have been proposed attempting to explain the pathogenesis of Alzheimer disease (AD) including theories involving amyloid deposition, tau phosphorylation, oxidative stress, metal ion dysregulation and inflammation. Strong evidence suggests that each one contributes to disease pathogenesis, though none of these mechanisms result in all the downstream changes that occur during the course of AD. For t Read More
-
-
-
Antioxidants as a Potential Therapy Against Age-Related Neurodegenerative Diseases: Amyloid Beta Toxicity and Alzheimer's Disease
Authors: P. Hajieva and C. BehlAlzheimer's disease (AD) is a progressive age-related neurodegenerative disorder with distinct neuropathological features. Extracellular plaques, consisting of aggregated amyloid peptides of 39-43 amino acids are one of the most prominent pathological hallmarks of this disease. Although the exact neurochemical effector mechanism of Aβ aggregation is not yet elucidated, age-associated disturbances of metal ion metabolism Read More
-
-
-
Neuroprotective Therapies for Alzheimer's Disease
Authors: Anke Huber, Grant Stuchbury, Alexander Burkle, Jim Burnell and Gerald MunchOne of the major age-related damaging agents are reactive oxygen species (ROS). The brain is more vulnerable to oxidative stress than other organs as concomitant low activity and capacity of antioxidative protection systems allow for increased exposure of target molecules to ROS. Since neurons are postmitotic cells, they have to live with cellular damage accumulated over many decades. Increased levels of ROS (also ter Read More
-
-
-
Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimer's Disease
Authors: G. E. Ringheim and A. M. SzczepanikAlzheimer's disease (AD) represents one of the most common ailments afflicting the rapidly growing elderly segment of today's population. Despite the vast amount of effort expended in developing a cure, currently approved drugs address only cognitive symptoms that, although important for improving a patient's daily living standard, do not provide a significant delay or halt to disease progression. Early reports that individuals Read More
-
-
-
Mitochondria: A Target for Neuroprotective Interventions in Cerebral Ischemia-Reperfusion
Authors: Morin Christophe and Simon NicolasEvidence obtained over the past two decades shows that reactive oxygen species (ROS) are involved in brain lesions, including those due to cerebral ischemia-reperfusion. The mitochondria are the primary intracellular source of ROS, as they generate huge numbers of oxidative-reduction reactions and use massive amounts of oxygen. When anoxia is followed promptly by reperfusion, the resulting increase in oxy Read More
-
-
-
Fatty Acid Amide Hydrolase: A Potential Target for Next Generation Therapeutics
More LessEndocannabinoids are amides, esters and ethers of long chain polyunsaturated fatty acids, which act as new lipid mediators. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol are the main endogenous agonists of cannabinoid receptors, able to mimic several pharmacological effects of Δ9-tetrahydrocannabinol, the active principle of Cannabis sativa preparations like hashish and marijuana. Th Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
